These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24079361)

  • 21. [Optimization of a floating osmotic pump system of ambroxol hydrochloride using central composite design-response surface methodology and its pharmacokinetics in Beagle dogs].
    Zhao F; Ma YL; Jin XL; Wang J; Cao DY
    Yao Xue Xue Bao; 2011 Dec; 46(12):1507-14. PubMed ID: 22375427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extrudable core system: development of a single-layer osmotic controlled-release tablet.
    Waterman KC; MacDonald BC; Roy MC
    J Control Release; 2009 Mar; 134(3):201-6. PubMed ID: 19100796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro characterization of a formulation of butorphanol tartrate in a poloxamer 407 base intended for use as a parenterally administered slow-release analgesic agent.
    Laniesse D; Smith DA; Knych HK; Mosley C; Guzman DS; Beaufrère H
    Am J Vet Res; 2017 Jun; 78(6):677-687. PubMed ID: 28541144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral hydromorphone extended-release.
    Guay DR
    Consult Pharm; 2010 Dec; 25(12):816-28. PubMed ID: 21172762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled porosity osmotic pump for the delivery of flurbiprofen.
    Chauhan CS; Choudhury PK
    Curr Drug Deliv; 2006 Apr; 3(2):193-8. PubMed ID: 16611005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).
    Okimoto K; Tokunaga Y; Ibuki R; Irie T; Uekama K; Rajewski RA; Stella VJ
    Int J Pharm; 2004 Nov; 286(1-2):81-8. PubMed ID: 15501004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nano-suspension coating as a technique to modulate the drug release from controlled porosity osmotic pumps for a soluble agent.
    Bahari LA; Javadzadeh Y; Jalali MB; Johari P; Nokhodchi A; Shokri J
    Colloids Surf B Biointerfaces; 2017 May; 153():27-33. PubMed ID: 28208062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration.
    Wells SM; Glerum LE; Papich MG
    Am J Vet Res; 2008 Dec; 69(12):1548-54. PubMed ID: 19045999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus.
    Lim GJ; Ishiuji Y; Dawn A; Harrison B; Kim DW; Atala A; Yosipovitch G
    Acta Derm Venereol; 2008; 88(4):327-30. PubMed ID: 18709299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.
    Wermeling DP; Miller JL; Archer SM; Rayens MK; Rudy AC
    J Clin Pharmacol; 2005 Aug; 45(8):969-73. PubMed ID: 16027409
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine.
    Goldstein J; Gawel MJ; Winner P; Diamond S; Reich L; Davidson WJ; Sussman NM
    Headache; 1998; 38(7):516-22. PubMed ID: 15613167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Release mechanisms of a sparingly water-soluble drug from controlled porosity-osmotic pump pellets using sulfobutylether-beta-cyclodextrin as both a solubilizing and osmotic agent.
    Sotthivirat S; Haslam JL; Lee PI; Rao VM; Stella VJ
    J Pharm Sci; 2009 Jun; 98(6):1992-2000. PubMed ID: 18823032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology.
    Verma RK; Kaushal AM; Garg S
    Int J Pharm; 2003 Sep; 263(1-2):9-24. PubMed ID: 12954176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
    Riggs SM; Hawkins MG; Craigmill AL; Kass PH; Stanley SD; Taylor IT
    Am J Vet Res; 2008 May; 69(5):596-603. PubMed ID: 18447789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inlay osmotic pump tablets containing metformin and glipizide.
    Patel RB; Patel GN; Patel HR; Patel MM
    Drug Dev Ind Pharm; 2011 Oct; 37(10):1244-52. PubMed ID: 21466414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microporous bilayer osmotic tablet for colon-specific delivery.
    Chaudhary A; Tiwari N; Jain V; Singh R
    Eur J Pharm Biopharm; 2011 May; 78(1):134-40. PubMed ID: 21255646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
    Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
    Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and formulation of nano-porous controlled porosity osmotic pumps (CPOPs) containing a poorly water soluble drug, glibenclamide.
    B LA; Javadzadeh Y; Jalali MB; Nokhodchi A; Shokri J
    Pak J Pharm Sci; 2019 Sep; 32(5):1979-1986. PubMed ID: 31813861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
    Vachharajani NN; Shyu WC; Barbhaiya RH
    J Clin Pharmacol; 1997 Oct; 37(10):979-85. PubMed ID: 9505990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of an immediate and extended release oral morphine formulation utilizing the spheroidal oral drug absorption system in dogs.
    Aragon CL; Read MR; Gaynor JS; Barnhart MD; Wilson D; Papich MG
    J Vet Pharmacol Ther; 2009 Apr; 32(2):129-36. PubMed ID: 19290942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.